The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Whitney Glad Ijem - Canaccord Genuity Corp., Research Division - Analyst
: Whitney from Canaccord. On the topic of durability and kind of the typical patient, I guess, as you're having these conversations, are there patients
who are having this all might be 2 years, 5 years, 7 years, et cetera, conversation. And they say, I still am interested, but I want to wait until I'm --
my kid is born or whatever the life of that might be that they kind of want to preserve that treatment holiday, so to speak, for a particular time in
their life? And is that coming up a lot in conversations or not really?
Unidentified Company Representative
Not -- I mean, essentially, I hadn't thought about that, and the short answer is, it has not come up.
Unidentified Participant
The same with me. I haven't seen that kind of conversation. And perhaps one could also add to that, that the profile of patients who are interested
in gene therapy, exactly the kind of patients you're describing, they want to start family, they want to be more active, et cetera. And I haven't seen
that postponement on the basis that we just want to see how it evolves over time.
Unidentified Company Representative
I mean the contraception issue is real, right? We know that from the prescribing information. I mean if there's a guy who's really like, I'm going to
start a family like in the next few months, well, then yes, they'll have to postpone obviously. You have to postpone the gene therapy or have to
postpone the family, but yes.
Unidentified Participant
We have time for one more question.
|
